CHMP backs J&J’s myeloma bispecific Tecvayli, ahead of US decision
pharmaphorum
JULY 25, 2022
J&J filed for approval of the bispecific in the US in December based on the results of the phase 1b MajesTEC-1 study in myeloma patients who had been treated with a median of five lines of prior therapy. Most patients diagnosed with myeloma will relapse over the course of their disease, so the disease is still considered incurable.
Let's personalize your content